Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

BioHorizons launches MinerOss X for dental implant site development procedures

BioHorizons, an oral reconstructive device company, today announced the launch of MinerOss X, a family of xenograft products for dental implant site development procedures. The MinerOss X family includes cancellous or cortical particulate, a moldable collagen block, and a cancellous particulate pre-loaded into a delivery syringe to assist with optimal placement.

12 Oct 2014

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute, it has received the 2014 Cancer Institute New South Wales Premier’s Award for Excellence in Translational Cancer Research.

17 Sep 2014

BGI-VPC Joint Research Laboratory to apply genome research to develop new cancer therapies

BGI, the world’s largest genomics organization, based in China, and The Vancouver Prostate Centre, a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including personalized oncology.

15 Sep 2014

Scientists find that DNA repair drug could help treat leukaemia, other cancers

A team of scientists led by Research Associate Professor Motomi Osato and Professor Yoshiaki Ito from the Cancer Science Institute of Singapore at the National University of Singapore found that a drug originally designed for killing a limited type of cancer cells with DNA repair defects could potentially be used to treat leukaemia and other cancers.

26 Aug 2014

Drug to kill limited type of cancer cells with DNA repair defects could treat leukaemia

A team of scientists led by Research Associate Professor Motomi Osato and Professor Yoshiaki Ito from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) found that a drug originally designed for killing a limited type of cancer cells with DNA repair defects could potentially be used to treat leukaemia and other cancers.

26 Aug 2014

Researchers aim to fight cancer by developing 'personalised' cancer therapies

Cancer is incredibly complex, and each tumour is unique. This calls for a targeted approach. Researchers at KU Leuven's Department of Oncology, in Belgium, want to fight cancer by developing 'personalised' cancer therapies. To bolster their efforts, they have established the new Fund for Innovative Cancer Research.

26 Jun 2014

Genetically modified swine skin grafts may provide new treatment for burn injuries

A specially-bred strain of miniature swine lacking the molecule responsible for the rapid rejection of pig-to-primate organ transplants may provide a new source of skin grafts to treat seriously burned patients.

28 May 2014

New in vitro 12-cell line panel assay predicts anti-cancer drug activity

Southern Research Institute today announced a new service offering - a novel in vitro 12-cell line panel assay designed to predict drug activity and improve the success rate of drugs tested in xenograft models.

21 May 2014

Six-way jet-in-air sorter from Beckman Coulter Life Sciences delivers simultaneous high-speed cell sorting and sub-micron particle detection

MoFlo Astrios EQ, a six-way jet-in-air sorter from Beckman Coulter Life Sciences, delivers patent pending enhanced dual forward scatter (eFSC) technology for simultaneous sorting and detection of particles from 200 nm to 30 µm in diameter. The instrument sets a new standard for flow cytometry core facilities, delivering high-speed cell sorting and micro-particle detection in a single package. Featuring detailed and precise forward scatter resolution, beadless drop sample handling and increased biosafety, Astrios EQ meets a range of analysis needs.

2 May 2014

Variant of cell surface protein may help develop drugs for gastric cancer

A team of scientists led by a researcher from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has identified the cancer specific stem cell which causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers.

25 Apr 2014

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

New study by the Cancer Science Institute of Singapore and National University Hospital Singapore suggests that a variant of a cell surface protein is an ideal target for developing drugs to treat gastric cancer

23 Apr 2014

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9.

11 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

8 Apr 2014

Novartis to present early stage data on 19 investigational compounds at AACR annual meeting

Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research, April 5-9, 2014 in San Diego, CA.

4 Apr 2014

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

2 Apr 2014

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

The discovery of a novel broad spectrum neuropeptide antagonist, peptide–1, which is related to the substance P analogue SP-G, could help develop treatments targeted at chemoresistant small-cell lung cancer, indicate study results.

1 Apr 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

Research shows depletion of cholesteryl ester impairs prostate cancer aggressiveness

Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new diagnostic and treatment methods.

5 Mar 2014

RNAi-based screening offers MPM treatment hope

Research using RNA interference-based screening has identified several potential targets for the treatment of malignant pleural mesothelioma.

31 Jan 2014